USD
+$0.00
(+0.00%
)At Close (As of Dec 11, 2025)
$73.74M
Market Cap
-
P/E Ratio
-9.42
EPS
$55.89
52 Week High
$5.20
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $2.3M |
| Total Revenue | $2.3M |
| Cost Of Revenue | $3.6M |
| Costof Goods And Services Sold | $3.6M |
| Operating Income | -$92M |
| Selling General And Administrative | $31M |
| Research And Development | $64M |
| Operating Expenses | $94M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $3.6M |
| Income Before Tax | -$83M |
| Income Tax Expense | $141K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$84M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$92M |
| Ebitda | -$88M |
| Net Income | -$84M |
| Field | Value (USD) |
|---|---|
| Total Assets | $226M |
| Total Current Assets | $132M |
| Cash And Cash Equivalents At Carrying Value | $56M |
| Cash And Short Term Investments | $56M |
| Inventory | - |
| Current Net Receivables | $1.7M |
| Total Non Current Assets | $95M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $37M |
| Short Term Investments | $70M |
| Other Current Assets | $3.7M |
| Other Non Current Assets | - |
| Total Liabilities | $66M |
| Total Current Liabilities | $15M |
| Current Accounts Payable | $4M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $1.3M |
| Total Non Current Liabilities | $51M |
| Capital Lease Obligations | $45M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $45M |
| Other Current Liabilities | $6.2M |
| Other Non Current Liabilities | $1.5M |
| Total Shareholder Equity | $160M |
| Treasury Stock | - |
| Retained Earnings | -$267M |
| Common Stock | $9K |
| Common Stock Shares Outstanding | $8.9M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $2.3M |
| Total Revenue | $2.3M |
| Cost Of Revenue | $3.6M |
| Costof Goods And Services Sold | $3.6M |
| Operating Income | -$92M |
| Selling General And Administrative | $31M |
| Research And Development | $64M |
| Operating Expenses | $94M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $3.6M |
| Income Before Tax | -$83M |
| Income Tax Expense | $141K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$84M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$92M |
| Ebitda | -$88M |
| Net Income | -$84M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Korro Bio, Inc. is a cutting-edge biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on pioneering RNA editing technologies to create advanced genetic medicines for a range of diseases. The company is dedicated to addressing significant unmet medical needs through its robust pipeline of innovative therapies, poised to transform treatment paradigms in multiple therapeutic areas. With a strong commitment to scientific excellence and patient-centric solutions, Korro Bio is strategically positioned to lead in the rapidly evolving genetic medicine market, driving both clinical impact and commercial success.